AbbVie

AbbVie is a global biopharmaceutical company founded in 2013 following the separation of Abbott Laboratories into two publicly traded companies. It is a publicly traded company on the New York Stock Exchange with a market capitalization of over $150 billion.

Headquartered in North Chicago, Illinois, AbbVie focuses on the discovery, development, and commercialization of drugs and other treatments for a variety of medical conditions, most notably in the areas of immunology, oncology, virology, and neuroscience. ABBVIE has a portfolio of more than 60 marketed products and a robust pipeline of potential new medicines. It also has a presence in more than 170 countries, with more than 39,000 employees.

AbbVie is one of the world's largest pharmaceutical companies, frequently ranking in the global top five by revenue.

AbbVie was established as a spinoff of Abbott Laboratories in January 2013, with the goal of becoming a research-based biopharmaceutical company focused on developing innovative drugs to address unmet medical needs. The separation was driven by Abbott's desire to separate its pharmaceutical business from its diversified medical products business, with AbbVie assuming ownership of Abbott's pharmaceutical assets. The new company began trading on the New York Stock Exchange in January 2013 under the symbol ABBV, and Richard Gonzalez was appointed CEO.

In its first year, AbbVie focused on building its portfolio of products and expanding its global reach. The company invested heavily in research and development, with a particular emphasis on immunology and oncology. AbbVie's flagship product, Humira, continued to be a top-selling drug globally, generating significant revenue for the company. In 2014, AbbVie announced that it had acquired the rights to develop and commercialize a new class of cancer drugs from Roche, which would further expand its oncology pipeline. The company also entered into strategic partnerships with several other organizations to advance the development of new therapies.

From 2016 to 2020, AbbVie continued to focus on research and development and expanding its portfolio of drugs. The company made several notable acquisitions, including Stemcentrx, a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, and Allergan, a pharmaceutical company specializing in aesthetics and neuroscience. These acquisitions expanded AbbVie's pipeline and increased its presence in key therapeutic areas.

In 2021, AbbVie continued to focus on innovation and expanding its pipeline. The company announced several new drug approvals and received positive clinical trial results for several drugs in development. Notably, the company's drug Skyrizi received approval from the FDA for the treatment of psoriatic arthritis, further expanding its use beyond psoriasis. AbbVie also received approval for a new treatment for Parkinson's disease and announced positive results for a drug used to treat multiple myeloma.

In addition to drug development, AbbVie has also focused on sustainability and corporate responsibility in recent years. The company has made commitments to reduce its environmental impact, improve diversity and inclusion within its workforce, and increase access to healthcare for underserved populations. 

The mission of AbbVie is to create an innovation-driven, patient-focused specialty biopharmaceutical company capable of achieving sustainable top-tier performance through outstanding execution and a consistent stream of innovative new medicines. 

They are focused on sustainable growth and addressing the world's pressing health challenges, inspiring hope and transforming lives every day, and discovering and delivering innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

AbbVie's vision is to improve the lives of people with serious health conditions and advance the understanding and treatment of complex diseases. The company strives to be a leader in the biopharmaceutical industry, developing innovative medicines that address unmet medical needs and provide meaningful benefits to patients. AbbVie's goal is to transform care and enhance outcomes for patients with conditions such as cancer, autoimmune diseases, neurological disorders, and more.

To achieve its vision, AbbVie focuses on scientific innovation, patient-centered research, and responsible corporate citizenship. The company is committed to investing in research and development, building partnerships and collaborations with other organizations, and ensuring access to its products for all patients who need them. AbbVie also seeks to minimize its environmental impact, improve diversity and inclusion within its workforce, and give back to the communities where it operates. 

AbbVie is a global pharmaceutical company that focuses on the research and development of advanced therapies for the treatment of serious diseases. The company offers a wide range of products and services that address various medical conditions, including immunology, oncology, neuroscience, virology, women's health, and gastroenterology.

In the immunology space, AbbVie's flagship product is Humira, a biologic therapy that is used to treat a variety of autoimmune diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease. The company also offers Skyrizi, a biologic treatment for moderate-to-severe psoriasis, and Rinvoq, an oral medication for the treatment of rheumatoid arthritis.

In oncology, AbbVie offers Imbruvica, a therapy that is used to treat certain types of blood cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma. The company also offers Venclexta, a therapy for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and Empliciti, a treatment for multiple myeloma.

AbbVie's neuroscience portfolio includes Duodopa, a therapy for advanced Parkinson's disease, and SkyeGY, a therapy for tardive dyskinesia. In the virology space, the company offers Mavyret, a treatment for hepatitis C, and Kaletra, a treatment for HIV. Additionally, AbbVie offers various patient support programs, clinical trials, and disease education resources to help patients and healthcare professionals manage complex medical conditions.